

Formulary Update

November 2020

The following changes to the Adult Medicines Formulary have been agreed during the ADTC or sub-committee meetings since March 2020. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Danazol	Endometriosis, hereditary angioedema	6.7.2	No UK licensed product available
Hydrocortisone rectal foam		1.5.2	Product discontinued
Rolapitant	Nausea, vertigo	4.6	Marketing Authorisation withdrawn
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Infliximab subcutaneous injection	See relevant formulary entries	1.5.3, 10.1.3.0, 13.5.3.0	
Liothyronine sodium tablets	Hypothyroidism	6.2.1	New Drug Assessment
Omeprazole dispersible	Gastric acid control for first 2 weeks post bariatric surgery	1.3.5	Formulary appeal
Paliperidone (Trevicta®)	Schizophrenia	4.2.2	Formulary appeal
Changes in preferred brand	New preferred brand	Adult Medicines Formulary entry	
Infliximab	Remsima®	10.1.3.0, 13.5.3.0, 1.5.3	
Insulin glargine	Semglee®	6.1.1.2	
Mycophenolic acid	Ceptava®	8.2.1	
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Olanzapine	Restrictions changed	4.2.1	Formulary appeal

Contact us [here](#)